Osimertinib plus anlotinib for advanced NSCLC with acquired EGFR T790M mutation: results from a multicenter phase II study with ctDNA analysis

Authors

Richeng Jiang (ORCID: https://orcid.org/0000-0002-3757-2219)
Yan Liang (ORCID: https://orcid.org/0000-0003-4029-1765)
Fuchao Chen (ORCID: https://orcid.org/0000-0001-9738-6744)
Dingzhi Huang
Zhaona Li (ORCID: https://orcid.org/0000-0001-8260-7460)
Song Xia (ORCID: https://orcid.org/0000-0002-1962-4273)
Xinyue Wang (ORCID: https://orcid.org/0000-0003-4231-617X)
Changli Wang (ORCID: https://orcid.org/0000-0003-0482-5889)
Chun Huang (ORCID: https://orcid.org/0000-0002-3626-7140)
Cuimin Ding
Liuchun Wang

Institutions

Shanxi Provincial Cancer Hospital (CN)

Publication Details

Journal: BMC Medicine
Published: 2025-04-15
DOI: https://doi.org/10.1186/s12916-025-04044-8
Citations: 3
Primary Topic: Lung Cancer Treatments and Mutations
Type: article
Field-Weighted Citation Impact: 4.56

Funders

National Natural Science Foundation of China

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Osimertinib plus anlotinib for advanced NSCLC with acquired EGFR T790M mutation: results from a multicenter phase II study with ctDNA analysis

Richeng Jiang, Yan Liang, Fuchao Chen, Dingzhi Huang et al.

Apr 15, 2025

3 citations

BMC Medicine

Lung Cancer Treatments and Mutations

4.56

article

Osimertinib plus anlotinib for advanced NSCLC with acquired EGFR T790M mutation: results from a multicenter phase II study with ctDNA analysis

Richeng Jiang, Yan Liang, Fuchao Chen, Dingzhi Huang, Zhaona Li, Song Xia, Xinyue Wang, Changli Wang, Chun Huang, Cuimin Ding, Liuchun Wang

April 15, 2025article en

3 citations

Abstract

No abstract available for this paper.

BMC MedicineVol. 23(1)

Shanxi Provincial Cancer Hospital (CN)

National Natural Science Foundation of China

Openalex Percentile: Top 6%

Lung Cancer Treatments and Mutations

4.56

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Osimertinib plus anlotinib for advanced NSCLC with acquired EGFR T790M mutation: results from a multicenter phase II study with ctDNA analysis — Richeng Jiang, Yan Liang, et al. · BMC Medicine (2025) | TGRS Research Map | TGRS